Merck (MRK) faces a December 2028 patent expiration for Keytruda. The drug generates roughly half of total revenue. Merck split Human Health into two divisions to move faster on pricing and medical ...

Merck’s MRK stock has risen 32.3% in the past three months. The stock has also been trading above its 50-day and 200-day simple moving averages (SMAs) since early November, indicating sustained ...

Companies often implement stock splits when their share prices get prohibitively high, frequently $400 or higher. Splits usually take place when a stock is trading near all-time h ...

Merck (MRK) shares slid about 3% in premarket trading on Tuesday after the drugmaker issued a full-year 2026 outlook that came in below Wall Street expectations. The Rahway, New Jersey–based company ...

Merck is rated a buy, with strong earnings growth, rising cash flow, and balance sheet strength supporting a bullish outlook. Keytruda's double-digit growth and margin expansion drive MRK's profits, ...

A giant in the healthcare space, Merck (NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a ...